Showing 4061-4070 of 10490 results for "".
- LEO Science & Tech Hub and Epicore Biosystems Advance AD Collabhttps://practicaldermatology.com/news/leo-science-tech-hub-and-epicore-biosystems-advance-ad-collab/2460208/LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma A/S, is starting the next phase of a research collaboration in atopic dermatitis (AD) with Epicore Biosystems, a wearable microfluidics and biosensor spinout from Northwestern University’s Center for Bio-Inte
- Positive Phase 2 Results Seen With Galderma’s Proprietary Liquid Toxin for Frown Lineshttps://practicaldermatology.com/news/positive-phase-2-results-seen-with-galdermas-proprietary-liquid-toxin-for-frown-lines-2/2460170/Galderma’s novel liquid abotulinum toxin, QM1114, is safe and effective for the treatment of glabellar lines, according to Phase 2 study results. Pivotal Phase 3 trials for Galderma's liquid formulation of botulinum toxin type A for the treatment of glabellar lines are expecte
- Second US Patent Issued to Alastin Based On TriHex Technologyhttps://practicaldermatology.com/news/second-us-patent-issued-to-alastin-based-on-trihex-technology/2460092/Alastin Skincare, Inc. was issued a second U.S. Patent, No. 10,286,030 from the United States Patent and Trademark Office covering Alastin's platform TriHex Technology. The patent also covers a variety of topical compositions based on Alastin's TriHex Technology. The coma
- FDA Approves Stelara for Treatment of Adolescents with Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-stelara-for-treatment-of-adolescents-with-moderate-to-severe-plaque-psoriasis/2458010/The FDA approved an expanded indication for Janssen Biotech, Inc.'s Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Today's approval marks a significant mile
- Histogen's Growth Factor Technology Now Part of Allergan's Skin Care Linehttps://practicaldermatology.com/news/histogens-growth-factor-technology-now-part-of-allergan-skin-care-line/2458111/Histogen’s growth factor technology will be marketed as part of Allergan's skin care line within its recently acquired Regenica® Advanced Rejuvenation System. The Regenica line is based on multipotent CCM Complex (Cell Conditioned Media) which comprises active growth factors
- US Attorney Announces Charges Against Two Executives Tied to Philidor Pharmacy Schemehttps://practicaldermatology.com/news/us-attorney-announces-charges-against-two-executives-tied-to-philidor-pharmacy-scheme/2458373/The US Attorney’s Office, Southern District of New York has charged two executives in connection with the Philidor Pharmacy scheme that instigated a stock value plunge at Valeant when it was revealed last year. The US Attorney’s office will hold a press conference today to
- Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Directorhttps://practicaldermatology.com/news/valeant-pharmaceuticals-appoints-thomas-w-ross-sr-lead-independent-director/2458532/Valeant Pharmaceuticals International, Inc.'s Board of Directors appointed Thomas W. Ross, Sr. as its lead independent director. Mr. Ross, who has been a member of Valeant's Board since March 8, 2016, serves on the Board&#
- Dr. Reddy's and its Subsidiary Promius Pharma File Three NDAshttps://practicaldermatology.com/news/dr-reddys-and-its-subsidiary-promius-pharma-announce-filing-of-three-ndas/2458971/Dr. Reddy's Laboratories and its subsidiary, Promius Pharma, LLC filed three 505(b)(2) New Drug Applications (NDAs) with the FDA. The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies in
- Sotyktu Demonstrates Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque PsOhttps://practicaldermatology.com/news/sotyktu-demonstrates-durable-efficacy-and-consistent-safety-for-up-to-three-years-in-moderate-to-severe-plaque-pso/2462066/Bristol Myers Squibb’s
- Score: Droplette Micro-infuser Named one of Time Magazine's Best Inventions of 2022https://practicaldermatology.com/news/score-droplette-micro-infuser-named-one-of-time-magazines-best-inventions-of-2022/2461427/Droplette’s Micro-Infuser Device is one